REV 5901

• UNSPSC Description:

  REV 5901 is a competitive and orally active antagonist of leukotriene receptor, with a Ki of 0.7 μM. REV 5901 is also a 5-lipoxygenase inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved[1][2].

• Target Antigen:

  Leukotriene Receptor; Lipoxygenase

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/rev-5901.html

• Purity:

  99.0

• Solubility:

  DMF : 36 mg/mL (ultrasonic;warming)

• Smiles:

  OC(CCCCC)C1=CC=CC(OCC2=NC3=CC=CC=C3C=C2)=C1

• Molecular Weight:

  335.44

• References & Citations:

  [1]Inwegen RGV, et, al. REV 5901: an orally effective peptidoleukotriene antagonist, detailed biochemical/pharmacological profile. J Pharmacol Exp Ther. 1987 Apr;241(1):117-24.|[2]Anderson G, et, al. Effects of REV 5901, a 5-lipoxygenase inhibitor and leukotriene antagonist, on pulmonary responses to platelet activating factor in the guinea-pig. Br J Pharmacol. 1988 Aug;94(4):1115-22.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  101910-24-1